Abbott Laboratories (ABT) said Sunday its investigational, leadless Aveir Conduction System Pacing device showed safety and performance in a clinical feasibility study.
The device delivers conduction pacing to the heart's left bundle branch area by mimicking the heart's electrical rhythm, the company said.
Abbott also recently started enrolling patients in a clinical trial of up to 414 people to evaluate the safety and effectiveness of its investigational CSP Implantable Cardioverter-Defibrillator lead.
The US Food and Drug Administration recently granted breakthrough device designations to both the Aveir and CSP devices, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。